New use of anacardic acid and its salts for antifungal application for cosmetic purposes

Abstract

The invention relates to the use of anacardic acid and its salts for an antifungal application for cosmetic purposes as an anti-dandruff agent. (No figure)

Description

Title of the invention: New use of anacardic acid and its salts for an antifungal application for cosmetic purposes

[0001] The invention relates to a new use of anacardic acid and its salts for an antifungal application for cosmetic purposes. The invention relates to a cosmetic composition having an antifungal action. The invention relates to a dermatological composition having an antifungal action. CONTEXT OF THE INVENTION

[0002] Dandruff is small fragments (scales) of the scalp made up of dead cells that detach, spreading through the hair or falling onto the shoulders.

[0003] It is known that a microscopic fungus called Malas sezia furfur or pity-rosporum ovale is involved in excessive scaling of the scalp and the appearance of dandruff. This fungus is a lipophilic yeast, belonging to the group of Fungi imperfecti and forming part of the natural commensal flora of humans (present in practically 100% of the population on all skin types and its presence is completely normal).

[0004] Dandruff is a hair problem that affects almost one in two people, mainly young men. While not serious, it can have an impact on self-esteem and quality of life. Generally, a cosmetic treatment based on an anti-dandruff shampoo can help to overcome it, as well as specific treatments (lotions).

[0005] These shampoos generally contain: - an antifungal (which acts on the fungus); - a keratolytic (an exfoliant); - soothing agents to combat itching.

[0006] Normally, the scalp renews itself approximately every 21 days. However, in some cases, cell renewal cycles last only 5 to 7 days. These accelerated cycles are a consequence of seborrheic dermatitis of the skin. The precise cause of seborrheic dermatitis has not yet been fully elucidated, but it is thought to be linked to the proliferation of Malassezia furfur.

[0007] Cashew Nut Shell Liquid or CNSL is a natural oil derived from cashew nut shells. The main components of raw (natural) CNSL are phenolic compounds: anacardic acid, cardol and cardanol. Methyl cardol is also present, but in trace amounts (<5%).

[0008] Each of these compounds is itself a mixture of products, comprising a alkyl or alkenyl chain, said alkenyl chain having 1, 2 or 3 double bonds (Scheme 1):

[0009] [Chem.l] 85% G h X 15 to 20% trace cardamom 10% Scheme 1 - Chemical structures of the main constituents of natural CNSL.

[0010] One of the aims of the invention is to provide a new active ingredient applicable to the scalp.

[0011] Another object of the invention is to provide a new natural or naturally occurring compound, derived from plant and natural sources, as a cosmetic active substance.

[0012] Another aim of the invention is the recovery of CNSL compounds, derived from agricultural production waste, in the cosmetic field.

[0013] Another object of the invention is to provide a cosmetic composition for improving the condition of the scalp of a healthy individual.

[0014] Another aim of the invention is to provide a dermatological composition making it possible to prevent or treat a state of scalp dysfunction.

[0015] Use

[0016] An object of the present invention relates to the cosmetic use of at least one acid of formula (I) and / or one of its salts of formula (II),

[0017] [Chem.2] OH ü OH O XOH XO Gabon+ R ' R (0 (h)

[0018] in which: - R represents a linear alkyl chain of 15 carbon atoms, saturated or unsaturated, which may comprise one to several double bonds, in particular 1 to 3 double bonds, - (Cation+) represents the associated cation of the salt of formula (II) and is of organic or mineral origin,

[0019] as an anti-dandruff agent by topical application to prevent or limit the formation of dandruff on the healthy scalp of a healthy human subject.

[0020] The inventors unexpectedly found that the acid of formula (I) and its acid salts of formula (II) exhibit an antifungal action on the fungus strain Malassezia furfur, making it possible to be used as an anti-dandruff agent. These compounds exhibited an inhibitory activity on the growth of the fungus strain Malassezia furfur, demonstrated by the tests of examples 9 to 11. The term "anti-dandruff agent" means an active ingredient in the form of a compound or composition, capable of eliminating and / or limiting the presence or formation of dandruff, in particular on the scalp.

[0021] According to a particular embodiment, the invention relates to the use as defined above of at least one compound of formula (I).

[0022] According to a particular embodiment, the invention relates to the use as defined above of at least one compound of formula (II).

[0023] According to a particular embodiment, the invention relates to the use as defined above of at least one compound of formula (I) and of at least one compound of formula (II).

[0024] According to a particular embodiment, the invention relates to the use as defined above, in which R comprises from 0 to 3 double bonds, in particular 0, 1, 2 or 3 double bonds.

[0025] Advantageously, in the case of association of at least two compounds, the number of double bonds of the R group of each of said compounds is independent of one another.

[0026] According to a particular embodiment, the invention relates to the use as defined above, in which the cation (Cation+) is of organic origin.

[0027] According to a particular embodiment, the invention relates to the use as defined above, in which the cation (Cation+) is of mineral origin.

[0028] Advantageously, in the case of a combination of at least two compounds of formula (II), the cation (Cation+) of each of said compounds is independent of one another.

[0029] According to a particular embodiment, the invention relates to the use as defined above, in which said anti-dandruff agent also has keratolytic properties.

[0030] Furthermore, the compounds of formula (I) and its salts of formula (II) such as anacardic acids are also known to exhibit a keratolytic effect.

[0031] Thus the compounds of formula (I) and its salts of formula (II) have the advantage of being anti-dandruff agents both by their antifungal action on Malassezia furfur and by their keratolytic action.

[0032] “A keratolytic action” means a biological action enabling the keratin layer of the skin to be detached and eliminated.

[0033] According to a particular embodiment, the invention relates to the use as defined above, in which said anti-dandruff agent acts by an antifungal and keratolytic action.

[0034] According to a particular embodiment, the invention relates to the use as defined above, in which said anti-dandruff agent acts by an antifungal and exfoliating action.

[0035] “An exfoliating action” means a cosmetic action allowing detachment in strips or sheets.

[0036] According to a particular embodiment, the invention relates to the use as defined above, in which said salt is such that the cation (Cation+) associated with the anion derived from the acid is:

[0037] - mineral and chosen from alkali metals, in particular a sodium cation (Na+) or a potassium cation (K+), or

[0038] - organic and is a cationic form of a primary, secondary or tertiary amine.

[0039] According to a particular embodiment, the invention relates to the use as defined above, in which the cation (Cation+) associated with the anion derived from the acid is mineral and chosen from alkali metals.

[0040] Advantageously the cation (Cation+) is the sodium cation (Na+) or the potassium cation (K+).

[0041] According to a particular embodiment, the invention relates to the use as defined above, in which the cation (Cation+) associated with the anion derived from the acid is organic and is the cationic form of a primary or secondary or tertiary amine.

[0042] According to a particular embodiment, the invention relates to the use as defined above, in which said cation (Cation+) is an organic cation and is the cationic form of an organic amine or an amino acid.

[0043] According to a particular embodiment, the invention relates to the use as defined above, in which said cation (Cation+) is an organic cation and is the cationic form of an organic amine.

[0044] According to a particular embodiment, the invention relates to the use as defined above, in which said cation (Cation+) is an organic cation and is the cationic form of an amino acid.

[0045] According to a particular embodiment, the invention relates to the use as defined above, in which said organic cation (Cation+) is chosen from the cationic form of lysine, arginine and histidine.

[0046] Advantageously, said organic cation is lysine.

[0047] According to a particular embodiment, the invention relates to the use as defined above, in which said salt is such that the cation associated with the anion derived from the acid is:

[0048] - mineral and chosen from alkali metals, in particular a sodium cation (Na+) or a potassium cation (K+), or

[0049] - organic and is the cationic form of a primary or secondary amine or tertiary,

[0050] in particular wherein said cation is an organic cation and is the cationic form of an organic amine or an amino acid,

[0051] preferably wherein said organic cation is chosen from the cationic form of lysine, arginine or histidine.

[0052] According to a particular embodiment, the invention relates to the use as defined above, in which each group R of said acid(s) of formula (I) and / or one of its salts of formula (II), is independently of one another: - a linear alkyl chain of 15 saturated carbon atoms, or - a linear alkyl chain of 15 monounsaturated carbon atoms comprising a double bond, or - a linear alkyl chain of 15 di-unsaturated carbon atoms comprising two double bonds, or - a linear alkyl chain of 15 tri-unsaturated carbon atoms comprising three double bonds.

[0053] According to a particular embodiment, the invention relates to the use as defined above, in which the anti-dandruff agent is an acid of formula (I) in which the R group is: - a linear alkyl chain of 15 saturated carbon atoms, or - a linear alkyl chain of 15 monounsaturated carbon atoms comprising a double bond, or - a linear alkyl chain of 15 di-unsaturated carbon atoms comprising two double bonds, or - a linear alkyl chain of 15 tri-unsaturated carbon atoms comprising three double bonds.

[0054] According to a particular embodiment, the invention relates to the use such as

[0055] defined above, in which the anti-dandruff agent is an acid of formula (I) chosen from acids A, B, C and D of the following formulas: [Chem. 3] OH O A (Ci 5 G; OH O C iGhOO OH O D (Cl 5:3)

[0056]

[0057] According to a particular embodiment, the invention relates to the use as defined above, in which the anti-dandruff agent consists of a mixture of 4 acids (AA0, AA1, AA2, AA3) of formula (I), in which: - the R group of AA0 acid is a linear chain of 15 saturated carbon atoms, - the R group of the AAI acid is a linear alkyl chain of 15 mono-unsaturated carbon atoms comprising a double bond, - the R group of the AA2 acid is a linear alkyl chain of 15 di-unsaturated carbon atoms comprising two double bonds, and - the R group of AA3 acid is a linear alkyl chain of 15 tri-unsaturated carbon atoms comprising three double bonds. According to a particular embodiment, the invention relates to the use as defined above, in which the anti-dandruff agent consists of a mixture of 4 acids A, B, C and D of the following formulas:

[0058] [Chem. 4] 8(015:1) C (C15;2) D (Cl 5:3)

[0059]

[0060] According to a particular embodiment, the invention relates to the use as defined above, in which the anti-dandruff agent is a salt of an acid, of formula (II), in which the R group is: - a linear alkyl chain of 15 saturated carbon atoms, or - a linear alkyl chain of 15 monounsaturated carbon atoms comprising a double bond, or - a linear alkyl chain of 15 di-unsaturated carbon atoms comprising two double bonds, or - a linear alkyl chain of 15 tri-unsaturated carbon atoms comprising three double bonds. According to a particular embodiment, the invention relates to the use as defined above, in which the anti-dandruff agent is a salt of an acid, of formula (II), of associated cation (Cation+), said salt being chosen from the compounds of the following formulas:

[0061] [Chem.5] OH O Cation4' v. W 0' (SAQ) OH O Cation" (SA1) OH O (SA2) OH O {SA3)

[0062] According to a particular embodiment, the invention relates to the use as defined above, in which the anti-dandruff agent consists of a mixture of 4 salts of the acids (SA0, SA1, SA2, SA3) of formula (II), in which: - the R group of the SA0 acid is a linear chain of 15 saturated carbon atoms, - the R group of the SA1 acid is a linear alkyl chain of 15 mono-unsaturated carbon atoms comprising a double bond, - the R group of the SA2 acid is a linear alkyl chain of 15 di-unsaturated carbon atoms comprising two double bonds, and - the R group of the acid S A3 is a linear alkyl chain of 15 tri-unsaturated carbon atoms comprising three double bonds.

[0063] According to a particular embodiment, the invention relates to the use as defined above, in which the anti-dandruff agent consists of a mixture of four acid salts of the following formulae:

[0064] [Chem.6] OH O Cation* OH • SAQ) (SA1) (SA2) OH O (SA3)

[0065] According to a particular embodiment, the invention relates to the use as defined above, in which said salts are lysine salts.

[0066] According to a particular embodiment, the invention relates to the use as defined above, in which the anti-dandruff agent is a lysine salt chosen from the following formulas:

[0067] [Chem. 7] NH2 (Lysine SAO) (Lysine SA1) NH2 (Lysine SA2) NH2

[0068] (Lysine SA3) According to a particular embodiment, the invention relates to the use as defined above, in which the anti-dandruff agent consists of a mixture of four lysine acid salts of the following formulas:

[0069] [Chem. 8] (Lysine SAO) OH O 'Nh< 0' (Lysine SA H (Lysine SA2) (Lysine S A3)

[0070]

[0071] According to a particular embodiment, the invention relates to the use as defined above, in which the R group is a saturated linear alkyl chain of 15 carbon atoms. According to a particular embodiment, the invention relates to the use as defined above, in which each R group of said acid(s) of formula (I) and / or one of its salts of formula (II), is independently of one another: a linear alkyl chain of 15 saturated carbon atoms, or a linear alkyl chain of 15 monounsaturated carbon atoms comprising a double bond, or - a linear alkyl chain of 15 diunsaturated carbon atoms comprising two double bonds, or - a linear alkyl chain of 15 tri-unsaturated carbon atoms comprising three double bonds,

[0072] in particular in which said salts of formula (II) are lysine salts,

[0073] preferably in which the group R is a linear alkyl chain of 15 saturated carbon atoms.

[0074] According to a particular embodiment, the invention relates to the use as defined above, in which the acid of formula (I) is of formula (AA) and / or one of its salts is of formula (LA) following:

[0075] [Chem.9] OH O (AA) (THERE)

[0076] According to a particular embodiment, the invention relates to the use as defined above, in which the acid of formula (I) is of the following formula (AA):

[0077] [Chem. 10] OH O To A OH (AA)

[0078] According to a particular embodiment, the invention relates to the use as defined above, in which one of its salts of formula (II) is of the following formula (LA):

[0079] [Chem. 11] ,-v X ÛH OH O WV' y Y o tXAz^z^ (THERE)

[0080] According to a particular embodiment, the invention relates to the use as defined above, in which said at least one acid and / or one of its salts is derived or prepared from cashew nut shell oil (CNSL).

[0081] Advantageously, said at least one acid and / or one of its salts are of natural origin.

[0082] According to a particular embodiment, the invention relates to the use as defined above, in which the total concentration of said at least one acid and / or one of its salts is from 0.025 to 2.500% m / v, preferably from 0.050 to 1.000% m / v.

[0083] The range of “0.025 to 2.500% w / v” includes the following ranges of values:

[0084] from 0.025 to 0.030% m / v; from 0.030 to 0.035% m / v; from 0.035 to 0.040% m / v; 0.040 to 0.045% w / v; 0.045 to 0.050% w / v;

[0085] from 0.050 to 0.100% w / v; from 0.100 to 0.200% w / v; from 0.200 to 0.300% w / v; from 0.300 to 0.400% w / v; from 0.400 to 0.500% w / v; from 0.500 to 0.600% w / v; from 0.600 to 0.700% w / v; from 0.700 to 0.800% w / v; from 0.800 to 0.900% w / v; from 0.900 to 1.000% w / v;

[0086] from 1,000 to 1,100% w / v; from 1,100 to 1,200% w / v; from 1,200 to 1,300% w / v; from 1,300 to 1,400% w / v; from 1,400 to 1,500% w / v; from 1,500 to 1,600% w / v; from 1,600 to 1,700% w / v; from 1,700 to 1,800% w / v; from 1,800 to 1,900% w / v; from 1,900 to 2,000% w / v;

[0087] from 2,000 to 2,100 m / v %; from 2,100 to 2,200 % m / v; from 2,200 to 2,300 % m / v; from 2,300 to 2,400 % m / v; from 2,400 to 2,500 % m / v.

[0088] The range of "0.050 to 1.000% w / v" includes the following ranges of values:

[0089] from 0.050 to 0.055% w / v; from 0.055 to 0.060% w / v; from 0.060 to 0.065% w / v; from 0.065 to 0.070% w / v; from 0.070 to 0.075% w / v; from 0.075 to 0.080% w / v; from 0.080 to 0.085% w / v; from 0.085 to 0.090% w / v; from 0.090 to 0.095% w / v; from 0.095 to 0.100% w / v;

[0090] from 0.100 to 0.125% m / v; from 0.125 to 0.150% m / v; from 0.150 to 0.175% m / v; from 0.175 to 0.200% m / v;

[0091] from 0.200 to 0.225% m / v; from 0.225 to 0.250% m / v; from 0.250 to 0.275% m / v; from 0.275 to 0.300% m / v;

[0092] from 0.300 to 0.325% w / v; from 0.325 to 0.350% w / v; from 0.350 to 0.375% w / v; from 0.375 to 0.400% w / v;

[0093] from 0.400 to 0.425% m / v; from 0.425 to 0.450% m / v; from 0.450 to 0.475% m / v; from 0.475 to 0.500% m / v;

[0094] from 0.500 to 0.525% w / v; from 0.525 to 0.550% w / v; from 0.550 to 0.575% w / v; from 0.575 to 0.600% w / v;

[0095] from 0.600 to 0.625% w / v; from 0.625 to 0.650% w / v; from 0.650 to 0.675% w / v; from 0.675 to 0.700% w / v;

[0096] from 0.700 to 0.725% w / v; from 0.725 to 0.750% w / v; from 0.750 to 0.775% w / v; from 0.775 to 0.800% w / v;

[0097] from 0.800 to 0.825% w / v; from 0.825 to 0.850% w / v; from 0.850 to 0.875% w / v; from 0.875 to 0.900% w / v;

[0098] from 0.900 to 0.925% w / v; from 0.925 to 0.950% w / v; from 0.950 to 0.975% w / v; from 0.975 to 1.000% w / v.

[0099] According to a particular embodiment, the invention relates to the use as defined above, in which said at least one acid and / or one of its salts is formulated in an anti-dandruff composition, in particular in the form of a lotion or a shampoo or a conditioner or a cream or a hair mask.

[0100] According to a particular embodiment, the invention relates to the use as defined above, in which said at least one acid and / or one of its salts is derived or prepared from cashew nut shell oil (CNSL),

[0101] and / or wherein the total concentration of said at least one acid and / or one of its salts is from 0.025 to 2.500% w / v, preferably from 0.050 to 1.000% w / v,

[0102] and / or wherein said at least one acid and / or one of its salts is formulated in an anti-dandruff composition, in particular in the form of a lotion or a shampoo or a conditioner or a cream or a hair mask.

[0103] Another subject of the invention relates to an anti-dandruff composition comprising as active ingredient, in a physiologically acceptable medium for topical application to healthy scalp, - said at least one acid of formula (I) and / or one of its salts of formula (II) as defined according to the invention above,

[0104] as a sole anti-dandruff agent, said anti-dandruff agent exhibiting antifungal action,

[0105] said active ingredient being present at a concentration of 0.025 to 2.500% w / v, preferably 0.050 to 1.000% w / v.

[0106] According to a particular embodiment, the invention relates to an anti-dandruff composition as defined above, comprising as active ingredient, in a physiologically acceptable medium for topical application to healthy scalp, - said at least one acid of formula (I) and / or one of its salts of formula (II) as defined according to the invention above, as an anti-dandruff agent, in particular as the sole anti-dandruff agent,

[0107] said anti-dandruff agent having an antifungal action,

[0108] said active ingredient being present at a concentration of 0.025 to 2.500% w / v, preferably of 0.050 to 1.000% w / v.

[0109] According to a particular embodiment, the invention relates to an anti-dandruff composition as defined above, in which the anti-dandruff agent has an antifungal action and also has keratolytic properties.

[0110] According to a particular embodiment, the invention relates to an anti-dandruff composition as defined above, in which said composition is free from other anti-dandruff agents.

[0111] According to a particular embodiment, the invention relates to an anti-dandruff composition as defined above, comprising as active ingredient, in a physiologically acceptable medium for topical application to healthy scalp, - said at least one acid of formula (I) and / or one of its salts of formula (II) as defined according to the invention above, as sole anti-dandruff agent,

[0112] said anti-dandruff agent having an antifungal action,

[0113] said active ingredient being present at a concentration of 0.025 to 2.500% w / v, preferably of 0.050 to 1.000% w / v.

[0114] According to a particular embodiment, the invention relates to an anti-dandruff composition as defined above, in which said single anti-dandruff agent has an antifungal action and also has keratolytic properties.

[0115] According to a particular embodiment, the invention relates to an anti-dandruff composition as defined above, in the form of a lotion or a shampoo or a conditioner or a mask or a hair cream.

[0116] According to a particular embodiment, the invention relates to an anti-dandruff composition as defined above, in which the anti-dandruff agent has an antifungal action and also has keratolytic properties,

[0117] and / or is in the form of a lotion or a shampoo or a conditioner or a hair mask or cream.

[0118] According to a particular embodiment, the invention relates to an anti-dandruff composition as defined above, in which said single anti-dandruff agent has an antifungal action and also has keratolytic properties,

[0119] and / or is in the form of a lotion or a shampoo or a conditioner or

[0120]

[0121]

[0122]

[0123]

[0124]

[0125]

[0126]

[0127]

[0128]

[0129]

[0130]

[0131] of a hair mask or cream. According to a particular embodiment, the invention relates to an anti-dandruff shampoo as defined above, comprising: - 0.025 to 2.500% w / v, preferably 0.050 to 1.000% w / v of active ingredient having antifungal action, in particular against Malasseziafurfur. Another subject of the present invention relates to a non-therapeutic cosmetic process for preventing and / or limiting the formation of dandruff on the scalp, comprising at least one step of topical application to a healthy scalp (of a healthy human subject) of a composition comprising at least one acid of formula (I) and / or one of its salts of formula (II) as defined above, optionally followed by a rinsing step. Another subject of the invention relates to a composition comprising at least one acid of formula (I) and / or at least one of its salts of formula (II): [Chem. 12] OH O OH O AA AI - 'OH 'O Cation œ on in which: - R represents a linear alkyl chain of 15 carbon atoms, saturated or unsaturated, which may comprise one to several double bonds, in particular 1 to 3 double bonds, - (Cation+) represents the associated cation of the salt of formula (II) and is of organic or mineral origin, for its use in preventing and / or treating localized and / or systemic infections caused by the fungal strain Malas seziafurfur. Examples Example 1: Synthesis of anacardic acid contained in natural CNSL Extraction step of natural CNSL from cashew nut shells Natural CNSL was obtained from cashew nut shells by a solvent extraction process. The required mass of previously ground cashew nut shells was suspended in the desired solvent (ethyl acetate, mass concentration of: shells / Vsolvent = 1 / 2.5) at 50 °C for 3 h. The suspension was then filtered, the shells were washed with solvent, and then the filtrates were combined. Natural CNSL was obtained after removal of the solvent. Thus, 160 kg of previously crushed cashew shells were introduced into a

[0132] filter bottom tank equipped with a felt filter cloth (apparent porosity of approximately 25 qm). 360 kg of ethyl acetate (i.e. 400 L) were then added to the tank. The suspension was then stirred at 50°C for 3 h. Vacuum filtration was then carried out to separate the filtrate from the extracted shell residues. 216 kg of ethyl acetate (240 L) were then introduced into the filter bottom tank and the suspension was again stirred at 50°C for 30 minutes. A second vacuum filtration was carried out to separate the filtrate from the extracted shell residues. The two filtrates were then combined, and the solvent was removed under reduced pressure using a falling film concentrator, at an evaporation temperature between 25 and 50°C. 56.6 kg of natural CNSL are thus obtained (black oil, the mass percentage of ethyl acetate is 13.4%, yield r = 31% excluding ethyl acetate). H-NMR (400 MHz, CDC13): 7.35 (t, J = 7.9 Hz, Hacid anacardium), 7.13 (t, J = 7.6 Hz, H cardanoiX 6.88 6.86 (m, Hatdde anacardium), 6.78 6.74 (m, Hatdde anacardium and Hcardan olX 6.66-6.63 (m, Hcardanoi), 6.24 (m, Hcardoi and Hmethyicardoi), 6.18 (s, Hcardoi), 5.87 5.76 (m, Hc-c), 5.46 - 5.30 (m, Hc^), 5.07 - 4.96 (m, Hc^), 2.99 - 2.96 (m, Hacidacardic), 2.82 - 2.76 (m, Lateral Hcdaine), 2.57 2.53 (m, Hcardanoi), 2.50 2.43 (m, Hcardoi and Hmdthyicardoi), 2.10 (s, H methyl cardol), 2.11 2.00 (m, Lateral Hcdaine), 1.63 1.53 (m, Lateral Hcdaine), 1.40 1.25 (m, H side chain), 0.93 0.86 (m, side chain)*

[0133] Precipitation step of the anacardic acid contained in natural CNSL

[0134] Anacardic acid was isolated from CNSL by a precipitation method in the presence of a base and a divalent cation. The process consisted of solubilizing the natural CNSL in a 95 / 5 V / V ethanol / water mixture, then precipitating the anacardic acid contained in the oil by adding calcium hydroxide (> 35% by mass). The suspension was left stirring at 50°C for 3 hours. It was then filtered to recover the anacardate salt. The latter was then acidified with a concentrated HCl solution to reprotonate the anacardic acid, then the product of interest was isolated from the aqueous phase by L / L extraction. The latter is in the form of a mixture of 4 major species:

[0135] [Chem. 13] - A: 6-pentadecyhal acid^ - B: 6-[8(Z) — pentadeceuyî] sahcylic acid - C: 6-[8(Z), H (Z) - pentadecadieiiyl] salicylic acid - D; 6-(8(2),. 11(2).14 - pentedecatenyl] salicylic acid OH OR “Saturated (A) (p '^Y' "OH ' ' Monoene (B) 'p ' xz xz 'x / X Diene (C) 'Z xz xz Xz ^x^XZ'Xj Thëne (D)

[0136] Precipitation of anacardic acid contained in natural CNSL

[0137] A quantity of 4.65 kg of natural CNSL comprising a residual mass percentage of ethyl acetate of 13.2%, was solubilized in 14 L of ethanol (96%) and 700 mL of tap water, in a 25 L reactor by stirring at 50°C. 1.6 kg of calcium hydroxide (at 96% purity), corresponding to 38% by mass relative to the CNSL, were then added to the medium. The suspension was left stirring at 90 rpm at 50°C for 3 h, then it was transferred to a 30 L Nutsche filter. After filtration, the solid was rinsed with 2 X 4 L of ethanol, then it was suspended in 4 L of tap water and 8 L of ethyl acetate. 12 L of a 6 M hydrochloric acid solution were then added to the suspension. The latter was stirred until the solid was completely dissolved. The medium was left to stand for decantation, then the aqueous phase was extracted with 8 L of ethyl acetate.The two organic phases were then combined and transferred into a 50 L decanter. The final organic phase was washed with 2 x 12 L of saturated NaCl solution, then the solvent was removed under reduced pressure (rotary evaporator) at 50°C. The final product thus obtained is a brown paste (3.10 kg, yield r = 72% relative to the mass of CNSL, purity p = 94%).

[0138] H-NMR (400 MHz, CDC13): 7.36 (1H, t, J = 8 Hz), 6.87 (1H, dd, J! = 8.4 and J2 = 1.2 Hz), 6.77 (1H, dd, J! = 7.4 and J2 = 1.2 Hz), 5.86 - 5.76 (m, Hc=c), 5.47 - 5.30 (m, Hc=c), 5.074 - 4.96 (m, Hc^), 2.99 - 2.95 (2H, m), 2.84 - 2.76 (m, Hlateral chain), 2.07 - 1.99 (m, Hlateral chain), 1.63 - 1.56 (m, Hchain iateria), 1.40 - 1.25 (m, H side chain), 0.92 - 0.86 (m, H side chain)*

[0139] Example 2: Synthesis of hydrogenated anacardic acid

[0140] Hydrogenation step

[0141] Hydrogenated anacardic acid A (C15:0) can be obtained by catalytic hydrogenation of the mixture of the four anacardic acid molecules (A, B, C and D) obtained in the precipitation step described in Example 1. This hydrogenation was carried out in a polar protic solvent, in the presence of a source of dihydrogen and a catalyst (such as a palladium catalyst supported on a carbon support (Pd / C) for example). The suspension was left stirring at room temperature under a dihydrogen atmosphere until the double bonds of the side chains of the anacardic acid molecules B, C and D disappeared (kinetic monitoring by NMR). The suspension was then filtered and the hydrogenated anacardic acid (A) was recovered after removal of the solvent from the filtrate.

[0142] Recrystallization step

[0143] Hydrogenated anacardic acid (A) is recrystallized from an alkane solvent (such as cyclohexane) to obtain a creamy white solid after drying.

[0144] Preparation by hydrogenation followed by recrystallization

[0145] 55.44 g of anacardic acid (1.61.10 1 mol, 1 eq.) were solubilized in 250 mL of ethanol (96%) by stirring at room temperature. 2.01 g of a 5% Pd / C catalyst (i.e. 3.6% by mass relative to the anacardic acid) were then added to the medium. The latter was bubbled under argon for 10 minutes, then under dihydrogen for 15 minutes. The suspension was then left stirring and under dihydrogen atmosphere at room temperature for 22hl5. The suspension was then filtered using a millipore filter, then the solvent was removed under reduced pressure (rotary evaporator) at 50°C. Obtaining 53.99 g of hydrogenated anacardic acid (beige solid, yield r = 96.3%)

[0146] H-NMR (400 MHz, CDC13): 7.36 (1H, m), 6.88 (1H, dd, J! = 8.4 and J2 = 1.2 Hz), 6.78 (1H, dd, J! = 7.5 and J2 = 1.2 Hz), 3.01 - 2.96 (2H, m), 1.66 - 1.56 (2H, m), 1.40 -1.25 (24H, m), 0.91 - 0.86 (3H, m).

[0147] 40.1 g of hydrogenated anacardic acid were solubilized in 200 mL of cy cyclohexane at 80°C for 30 minutes. Once the medium was homogeneous, it was left to stand at room temperature for 1 hour, then it was immersed in a cold water bath (water + ice cubes) for 1 hour 30 minutes. A brown solid then formed in the medium. This solid was recovered by filtration on a porosity 4 frit, then it was washed on the frit with 60, then 2x70 mL of cold cyclohexane (previously stored at 5°C). The solid was then dried under reduced pressure (rotary evaporator) at 50°C, then it was dried using a vane pump at room temperature for 5h5. 27.069 g of a creamy white solid were thus obtained (yield r = 67.5%, purity p > 97% by HPLC).

[0148] H-NMR (400 MHz, acetone-d6): 7.35 - 7.31 (1H, m, J = 7.8 Hz), 6.79 - 6.77 (2H, m), 2.99 - 2.95 (2H, m), 1.60 (2H, m), 1.35 - 1.28 (24H, m), 0.89 - 0.86 (3H, m).

[0149] 13C-NMR (101 MHz, acetone-d6): 173.71, 163.65, 147.27, 134.86, 123.01, 116.08, 113.33, 36.86, 33.05, 32.70, 30.60-29.77, 23.39, 14.42.

[0150] SM (ESI -): m / z = 347.3 (MH).

[0151] Example 3: Preparation of anacardic acid salts

[0152] The salts are obtained by adding an equivalent of the salifying compound to anacardic acid, either to the mixture of the four anacardic acid molecules A, B, C and D, or to hydrogenated anacardic acid.

[0153] [Chem. 14] OH O / \ Se / s from Wiâfè anacard / qiye and from ©à from anacardic acid and lysine ff / fp

[0154] The salt of formula E (anacardic acids-triethylamine) is obtained by adding one equivalent of triethylamine, solubilized in ethanol, to an ethanolic solution of a mixture of anacardic acids A, B, C and D. The salt is obtained after removal of the solvent by lyophilization.

[0155] The salt of formula E' (hydrogenated anacardic acid-triethylamine) is obtained by adding one equivalent of triethylamine, solubilized in ethanol, to an ethanolic solution of hydrogenated anacardic acid. The salt is obtained after removal of the solvent by lyophilization.

[0156] Salts from anacardic acid and lysine

[0157] The salt of formula F (anacardic acids-lysine) is obtained by adding one equivalent of lysine, solubilized in water, to an ethanolic solution of a mixture of anacardic acids A, B, C and D. The salt is obtained after removal of the solvent by lyophilization.

[0158] The salt of formula F' (hydrogenated anacardic acid-lysine) is obtained by adding one equivalent of lysine, solubilized in water, to an ethanolic solution of hydrogenated anacardic acid. The salt is obtained after removal of the solvent by lyophilization.

[0159] Example 4: Preparation of hydrogenated anacardic acid-triethylamine salt (E')

[0160] 1.00 g of hydrogenated anacardic acid (2,841.103 mol, 1 eq.) were solubilized in 5 mL of absolute ethanol by stirring at room temperature. In parallel, 290 mg of triethylamine (99%, 2,841.103 mol, 1 eq.) were dissolved in 3 mL of absolute ethanol by stirring at room temperature. The triethylamine solution was then added dropwise into the ethanolic anacardic acid solution with 2 mL of absolute ethanol as a rinse. The medium was left stirring at room temperature for 15 minutes, then the solvents were removed by lyophilization for 6 h, then under vacuum using a vane pump for 4 h. 1.29 g of a pale pink solid were thus obtained (yield r = 99%).

[0161] H-NMR (400 MHz, CD3OD / D2O 90 / 10): 7.08 (1H, t, J = 7.8 Hz), 6.65 - 6.59 (2H, m), 3.18-3.12 (6H, m), 3.06 - 3.03 (2H, m), 1.59 - 1.52 (2H, m), 1.30 - 1.27 (33H, m), 0.88 (3H, t, J = 6.7 Hz).

[0162] NMR-13C (101 MHz, CD3OD / D2O 90 / 10): 176.0, 161.8, 147.1, 131.7, 122.4, 120.2, 114.9, 47.7, 36.2, 33.4, 33.0 31.0 - 30.7, 30.4, 23.7, 14.5, 9.2.

[0163] SM (ESI -): m / z anionic part (anacardate) = 347.3 (MH); (ESI +): m / z cationic part (triethylamine) = 102.1 (M+H)+.

[0164] Example 5: Preparation of the non-hydrogenated anacardic acid-triethylamine salt (E)

[0165] 1.009 g of anacardic acid (2,753.103 mol, 1 eq.) were solubilized in 10 mL of absolute ethanol by stirring at room temperature. In parallel, 279 mg of triethylamine (99%, 2,730.10 3 mol, 0.99 eq.) were dissolved in 3 mL of absolute ethanol by stirring at room temperature. The triethylamine solution was then added dropwise into the ethanolic anacardic acid solution with 2 mL of absolute ethanol as a rinse. The medium was left stirring at room temperature for 15 minutes, then the solvents were removed by lyophilization for 6 h, then under vacuum using a vane pump for 4 h. 1.217 g of a brown pasty solid were thus obtained (yield r = 95%).

[0166] H-NMR (400 MHz, CD3OD / D2O 90 / 10): 7.10 (1H, t, J = 7.8 Hz), 6.66 - 6.61 (2H, m), 5.85 - 5.75 (m), 5.44 - 5.29 (m), 5.05 - 4.94 (m), 3.18 - 3.12 (6H, m), 3.05 - 3.01 (2H, m), 2.82 - 2.74 (2H, m), 2.06 - 1.97 (m), 1.59-1.51 (2H, m), 1.36 - 1.26 (m), 0.92 - 0.86 (3H, m).

[0167] NMR-13C (101 MHz, CD3OD / D2O 90 / 10): 175.9, 161.7, 147.1, 137.9, 131.8, 131.2, 131.0, 130.9, 130.8, 130.7, 130.2, 129.2, 129.0, 128.6, 127.7, 122.4, 120.0, 115.1, 114.9, 36.2, 33.2, 32.8, 32.4, 30.8 - 30.2, 29.9, 28.1, 28.0, 26.5, 26.4, 23.8, 23.6, 14.5, 14.1, 9.2.

[0168] SM (ESI -): m / z anionic part (anacardate) = 341.2 (triene form), 343.2 (diene form), 345.2 (monoene form), 347.3 (saturated form) (MH); (ESI +): m / z cationic part (triethylamine) = 102.1 (M+H)+.

[0169] Example 6: Preparation of hydrogenated anacardic acid salt with lysine (F')

[0170] 6.092 g of hydrogenated anacardic acid (1,748.102 mol, 1 eq.) were brought to Lubricate in 60 mL of absolute ethanol by stirring at room temperature. In parallel, 2.612 g of L-lysine (98%, 1,751.102 mol, 1 eq.) were dissolved in 20 mL of distilled water by stirring at room temperature. The lysine solution was then added dropwise into the ethanolic anacardic acid solution with 10 mL of rinsing water. The medium was left stirring at room temperature for 15 minutes, then the solvents were removed under reduced pressure (rotary evaporator) at 50°C. The solid was dried by lyophilization for 16 h, then under vacuum using a vane pump for 7 h. 8.349 g of a pale pink solid were thus obtained (yield r = 95.9%).

[0171] H-NMR (400 MHz, CD3OD / D2O 90 / 10): 7.09 (1H, t, J = 7.8 Hz), 6.66 - 6.60 (2H, m), 3.61 (1H, t, J = 6.1 Hz), 3.05 - 3.01 (2H, m), 2.98 - 2.94 (2H, m), 1.91 - 1.85 (2H, m), 1.71 (2H, quintuplet, J = 7.6 Hz), 1.58 - 1.45 (4H, m), 1.30 - 1.25 (24H, m), 0.88 (3H, t, J = 6.7 Hz).

[0172] NMR-13C (101 MHz, CD3OD / D2O 90 / 10): 176.1, 174.9, 161.4, 147.0, 131.6, 122.4, 120.4, 114.8, 55.7, 40.3, 36.0, 33.1, 32.9, 31.5, 30.8 - 30.2, 28.0, 23.6, 22.9, 14.4.

[0173] SM (ESI -): m / z anionic part (anacardate) = 347.3 (MH); (ESI +): m / z cationic part (lysine) = 147.1 (M+H)+, 130.1 (M+H-NH3)+.

[0174] Example 7: Preparation of non-hydrogenated anacardic acid salt with lysine (F)

[0175] 1.00 g of anacardic acid (2,728.103 mol, 1 eq.) were solubilized in 10 mL of absolute ethanol by stirring at room temperature. In parallel, 407 mg of L-lysine (98%, 2,728.103 mol, 1 eq.) were dissolved in 3 mL of distilled water by stirring at room temperature. The lysine solution was then added dropwise into the ethanolic anacardic acid solution with 2 mL of rinsing water. The medium was left stirring at room temperature for 15 minutes, then the solvents were removed by lyophilization for 6 h, then under vacuum using a vane pump for 4 h. 1.014 g of a brown pasty solid were thus obtained (yield r = 72%).

[0176] H-NMR (400 MHz, CD3OD / D2O 90 / 10): 7.08 (1H, t, J = 7.8 Hz), 6.66 - 6.60 (2H, m), 5.85 - 5.75 (m), 5.44 - 5.29 (m), 5.04 - 4.94 (m), 3.61 (1H, t, J = 6.1 Hz), 3.05 -3.01 (2H, m), 2.97 - 2.93 (2H, m), 2.81 - 2.74 (m), 2.06 - 1.98 (m), 1.92 - 1.85 (2H, m), 1.71 (2H, quintuplet, J = 7.6 Hz), 1.59 - 1.45 (4H, m), 1.36 - 1.26 (m), 0.91 - 0.86 (3H, m).

[0177] NMR-13C (101 MHz, CD3OD / D2O 90 / 10): 176.2, 174.7, 161.4, 146.9, 137.9, 131.6, 131.2, 130.97, 130.9, 130.8, 130.7, 130.2, 129.2, 129.0, 128.6, 127.7, 122.4, 120.5, 115.2, 114.9, 55.7, 40.3, 36.1, 33.1, 32.8, 32.4, 31.5, 30.9 - 30.2, 29.9, 28.1 - 28.0, 26.5, 26.4, 23.8, 23.6, 23.0, 14.5, 14.2.

[0178] SM (ESI -): m / z anionic part (anacardate) = 341.2 (triene form), 343.2 (diene form), 345.2 (monoene form), 347.3 (saturated form) (MH); (ESI +): m / z cationic part (lysine) = 147.1 (M+H)+, 130.1 (M+H-NH3)+.

[0179] Example 8: Determination of CMI inhibitory activity

[0180] The purpose of this study is to evaluate the inhibitory activity of a test compound against the strain Malas sezia furfur using a micromethod on a microplate.

[0181] a) Principle of the test:

[0182] In a 96-well microplate, the following are brought into contact:

[0183] - 100 pL of the test compound at twice the concentration of the test concentration

[0184] - with 100 pL of a double strength nutrient broth titrating approximately between 2 and 6.105 cfu / mL (colony forming unit).

[0185] After incubation of the microplate for a defined period, the optical density at 620 nm of each well containing the compound to be tested at a defined concentration is measured. The results are expressed as a percentage of growth calculated relative to a growth control according to the following equation:

[0186] [Math.l] PottrrsntaÆfe «7? growth (DO compound at concentration C — DO control absorbance of compound at concentration C DO growth control

[0187] By definition, the first lowest concentration of compound to be tested allowing a growth percentage of less than or equal to 20% to be obtained is considered the inhibitory concentration.

[0188] b) Experimental conditions

[0189] The microbial strain tested is Malassezia furfur CBS 1878.

[0190] The strain comes from the Centraal Bureau voor Schimmelcultures (CBS).

[0191] It is maintained in the laboratory according to the requirements of standard NF EN 12353.

[0192] The composition of the nutritious broth is double-strength Sabouraud Broth with added olive oil.

[0193] The incubation temperature of the microplate is 30°C + / - 1°C in aerobiosis.

[0194] The incubation time of the microplate is 24 to 48 h in aerobiosis.

[0195] The preparation of the dilutions of the compounds to be tested is carried out from solutions mothers.

[0196] The stock solutions are prepared at 2% by diluting (Ethanol 96° / Sterile water - 90 / 10% v / v). Successive dilutions in 1% agar are carried out.

[0197] The chosen range of concentrations of the compound to be tested (by weight of the compound per volume) is:

[0198] of 0.01% m / v; 0.05% m / v; 0.10% m / v; 0.50% m / v and 1.0% m / v

[0199] The typical distribution of a 96-well microplate for assessing the inhibitory concentration of a test compound against Malassezia Furfur is illustrated in the following diagram:

[0200] [Chem. 15] Absorbance well Test well Test 1 Test 2

[0201] Thus the absorbance control wells comprise: - 100 μL of sterile double-strength nutrient broth - and 100 pL of the test compound at double concentration

[0202] The wells for the tests each comprise: - 100 pL of nutrient broth inoculated with Malassezia Furfur double concentration - and 100 pL of the test compound at double concentration

[0203] A growth control microplate is made separately by seeding the 96 wells with: - 100 pL of nutrient broth inoculated with Malassezia Furfur double concentration - and 100 pL of a 1% agar solution.

[0204] c) Expression of results

[0205] For each concentration of compound to be tested and for each test, the average of the DO values ​​measured on the 3 wells is taken and the growth percentages are calculated.

[0206] These values ​​are plotted on a graph (growth percentage as a function of concentration) in order to study the activity profiles of each compound to be tested.

[0207] Example 9: Inhibition tests with hydrogenated anacardic acid

[0208] Tables 1 and 2 below report respectively, for tests 1 and 2 carried out in the same microplate, the results of optical densities DO with hydrogenated anacardic acid as the compound to be tested according to the method of example 8 in which the percentage of growth is calculated from a growth control of DO measured at 0.599.

[0209] [Tables 1] TEST 1 - Hydrogenated Anacardic Acid Concentration (% w / v) 0.01 Q,O5 0.1 0.5 1 8 c D Average DO control absorbance 0.177 0.639 0.923 0.271 0.116 0.223 0.617 1.207 0.303 0.07 0.22 0.622 1.262 0.214 0.158 0.209 0.626 1.131 0.264 0.115 FGH Average DO compound to be tested 1.151 0.531 CÔ 0.236 0.074 1.268 0.666 1.173 0.273 0.107 1.277 0.619 1.156 0.217 0.117 1.232 0.639 1.202 0.262 0.099 Percentage growth (measured OD of growth control of 0.599) 171% 2% 12% 0% -3%

[0210] Table 1: Results of optical densities DO with hydrogenated anacardic acid as test compound and percentage growth calculated for a series of tests 1 on a microplate 1.

[0211] [T ables 2] TEST 2 - Hydrogenated anacardic acid Concentration (% w / v) 0.01 0.05 0.1 0.5 1 B Average DO control absorbance 0.57 0.59 1.299 0.147 0.137 0.268 0.445 1.434 0.131 0.062 0.294 0.59 1.207 0.236 0.156 0.377 0.542 1.313 0.188 0.118 GH Average DO test compound 1.746 0.591 1.317 0.224 0.068 1.451 0.59 1.13 0.222 0.108 0.953 0.656 1.235 0.234 0.106 1.383 0.612 1.227 0.227 0.094 Percentage growth (measured OD of growth control of 0.539) 168% 12% ■14% 6% -4%

[0212] Table 2: Results of optical densities DO with hydrogenated anacardic acid as test compound and percentage growth calculated for a series of tests 2 on a microplate 2.

[0213] Example 10: Inhibition tests with the lysine salt of anacardic acid hydrogen

[0214] Tables 3 and 4 below report respectively, for tests 1 and 2 carried out in the same microplate, the results of optical densities DO with the lysine salt of hydrogenated anacardic acid as the compound to be tested according to the method of example 8 in which the percentage of growth is calculated from a growth control of DO measured at 0.599.

[0215] [Tables3] TEST 1 - Lysine salt of hydrogenated anacardic acid Concentration 0.01 0.05 0.1. 0.5 1 B 0.171 0.44? 0.359 0.339 0.103 c 0.144 0.438 0.633 0.289 0.127 D 0.115 0.326 0.22 0.14 Average OD control absorbance 0.143 0.456 0.439 0.2836 0.123 F 1.144 0.348 3.615 0.252 0.171 G 1.123 0.434 0.249 0.363 0.167 H 1.129 PN Oh 0.242 0.217 0.143: Average OD compound to be tested 1.132 0.349 0.369 0.277 Percent growth (measured OD of the growth control of 0.539] 165% -18% -12% -1% 6%

[0216] Table 3: Results of optical densities OD with the lysine salt of hydrogenated anacardic acid as the test compound and percentage growth calculated for a series of tests 1 on a microplate 1.

[0217] [Tables4] TEST 2 - Lysine salt of hydrogenated anacardic acid F CMœntration m / v) aoi 0.05 0.1 G 5 1 S 0.193 0.347 0.633 0.27 0.095 c 0.157 0.443 0.599 0.217' Q. 102 D 0.166 0.375 0.256 0.146- 0.101 Mayenne DO control absorbance 0.172 0.496 0.211 0.099 F 1.252 0.31 0.352 G 2 0.097 G 1.124 0.283 0.473 0.144 0.083 H 1.256 0.151 0.712 0.233 0.106 Average DO compound to be tested 1.211 0.248 0.512 0.192 0.097 Growth percentage (measured OD of growth control of 0.595) 173% -23% 3% -3% 0%

[0218] Table 4: Results of optical densities OD with the lysine salt of hydrogenated ana-cardic acid as test compound and percentage growth calculated for a series of tests 2 on a microplate 2.

[0219] Example 11: Inhibitory activity

[0220] The synthesis of the results of examples 9 and 10 is presented in table 5 which reports the inhibitory concentrations (in % w / v) obtained with respect to Malassezia furfur for hydrogenated anacardic acid and a salt of hydrogenated anacardic acid (lysine salt).

[0221] [Tables5] Tested Compound jWassezra ftMur Test 1 Test 2 Hydrogenated Anacardic Acid (Acid) 0.05 0.05 Hydrogenated Anacardic Acid (Salt) (Lysine Salt) 0.05 0.05

[0222] Table 5: Inhibitory concentrations (in % w / v) obtained against Malassezia furfur for hydrogenated anacardic acid and a hydrogenated anacardic acid salt (lysine salt).

Claims

Claims

1. Cosmetic use of at least one acid of formula (I) and / or one of its salts of formula (II), [Chem. 16] QH 0 OH OXA XX..... . 'OH if 'O Cation RR (!) 01) in which: - R represents a linear alkyl chain of 15 carbon atoms, saturated or unsaturated, which may comprise one to several double bonds, in particular 1 to 3 double bonds, - (Cation+) represents the associated cation of the salt of formula (II) and is of organic or mineral origin, as an anti-dandruff agent by topical application to prevent or limit the formation of dandruff on the healthy scalp of a healthy human subject.

2. Use according to claim 1, wherein said salt is such that the cation associated with the anion derived from the acid is: - inorganic and chosen from alkali metals, in particular a sodium cation (Na+) or a potassium cation (K+), or - organic and is a cationic form of a primary, secondary or tertiary amine, in particular wherein said cation is an organic cation and is the cationic form of an organic amine or an amino acid, preferably wherein said organic cation is chosen from the cationic form of lysine, arginine or histidine.

3. Use according to one of claims 1 or 2, in which each R group of said acid(s) of formula (I) and / or one of its salts of formula (II), is independently of one another: a saturated linear alkyl chain of 15 carbon atoms, or a monounsaturated linear alkyl chain of 15 carbon atoms comprising a double bond, or

4. - a linear alkyl chain of 15 di-unsaturated carbon atoms comprising two double bonds, or - a linear alkyl chain of 15 tri-unsaturated carbon atoms comprising three double bonds, in particular in which said salts of formula (II) are lysine salts, preferably in which the R group is a saturated linear alkyl chain of 15 carbon atoms. Use according to one of claims 1 to 3, in which the acid of formula (I) is of formula (AA) and / or one of its salts is of formula (LA) following: [Chem. 17] OH O k I. (AA)

5.

6.

7. HA) Use according to one of claims 1 to 4, wherein said at least one acid and / or one of its salts is derived or prepared from cashew nut shell oil (CNSL). Use according to one of claims 1 to 5, wherein the total concentration of said at least one acid and / or one of its salts is from 0.025 to 2.500% w / v, preferably from 0.050 to 1.000% w / v, and / or wherein said at least one acid and / or one of its salts is formulated in an anti-dandruff composition, in particular in the form of a lotion or a shampoo or a conditioner or a cream or a hair mask. Anti-dandruff composition comprising as active ingredient, in a physiologically acceptable medium for topical application on healthy scalp, - said at least one acid of formula (I) and / or one of its salts of formula (II) [Chem. 18] OH 0 OH 0 XAAA - + rj' OH 'YO çafton R in which: - R represents a linear alkyl chain of 15 carbon atoms, saturated or unsaturated, which may comprise one to several double bonds, in particular 1 to 3 double bonds, - (Cation+) represents the associated cation of the salt of formula (II) and is of organic or mineral origin, as an anti-dandruff agent, in particular as the sole anti-dandruff agent, said anti-dandruff agent having an antifungal action, said active ingredient being present at a concentration of 0.025 to 2.500% w / v, preferably 0.050 to 1.000% w / v.

8. An anti-dandruff composition according to claim 7, wherein the anti-dandruff agent exhibits antifungal action and also has keratolytic properties, and / or is in the form of a lotion or shampoo or conditioner or hair mask or cream.

9. Non-therapeutic cosmetic process for preventing and / or limiting the formation of dandruff on the scalp, comprising at least one step of topical application to a healthy scalp (of a healthy human subject) of a composition comprising at least one acid of formula (I) and / or one of its salts of formula (II) as defined according to one of claims 1 to 4, optionally followed by a rinsing step.

10. Composition comprising at least one acid of formula (I) and / or minus one of its salts of formula (II): [Chem. 19] OH O OH O p"' 'OH Oal-on' W () in which: - R represents a linear alkyl chain of 15 carbon atoms, saturated or unsaturated, which may comprise one to several double bonds, in particular 1 to 3 double bonds, - (Cation+) represents the associated cation of the salt of formula (II) and is of organic or mineral origin, for its use in preventing and / or treating localized and / or systemic infections caused by the fungal strain Malassezia furfur.

Images